Physicians’ Perspectives on Cannabis Legalization – One year later

By Rahim Shah, VP Client Services

October 8, 2019

In October 2018, the use of recreational cannabis was legalized across Canada. Looking back at the past year, physicians remain divided in their views towards this new legislation, though support skews towards younger GPs. This legislation has impacted the use of prescription treatments and patient visits in a number of key therapeutic areas, though not to the degree that was anticipated 12 months ago. See the infographic for insights into Canadian physicians’ perspectives on the legalization of recreational cannabis.

Read More

Half of all GPs have observed an increase in recreational cannabis users within their practice. Support and opposition of the legalization of recreational cannabis is consistent across Canada. Supporters of the legislation are more likely to be younger physicians.

GPs have observed a decline in patient visits related to prescriptions for anxiety and severe stress (13%), chronic pain (17%) and insomnia (12%).  GPs have observed an increase in certain conditions/symptoms as a result of recreational cannabis use: anxiety, fear/panic (33%), dependence/misuse (32%), psychotic symptoms (27%) and effects on the brain (26%).

Despite the polarizing nature of this issue, supporters of recreational cannabis tend to skew younger, suggesting that acceptance of recreational cannabis is likely to remain, if not grow.

Past Quick Polls

COVID-19 Impact on Women in Pharma

The COVID-19 crisis changed the way people work across industries including the pharma industry. MD Analytics teamed up with the professional association for women in the pharma industry Women Leaders in Pharma to conduct a study on the impact on of COVID-19 on women who work in the pharma industry.

read more

Pandemic’s Impact on HCPs Practices and Vaccination Campaign Perceptions

The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward? Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19.

read more

Remote Detailing for Pharma – Physicians’ perspectives

Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.

read more

We are here to answer your questions.

Share This